CSIMarket Company Name, Ticker, Industry, else..



Best Performing Stocks In Major Pharmaceutical Preparations Industry During This Month Of April


 1 Day   Week  Current Month of April  30 Days 
Current Quarter Q2 of 2025  90 Days    Ytd    12 Months 
 

Shares fell by -2.36% on average, in Major Pharmaceutical Preparations Industry during this month of April.

Here are the best performing stocks in Major Pharmaceutical Preparations Industry.




GCAN

$0.0015

$0.0009 150.00%
This Month of April


GCAN

$0.0015

$0.0009 150.00%



The Greater Cannabis Company Inc

The Greater Cannabis Company Inc stock improved 150.00% during this month of April.


The Greater Cannabis Company Inc*s business model involves the cultivation, processing, and distribution of cannabis products. They aim to offer a wide range of cannabis-related goods to cater to the demands of both medical and recreational users.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.423 mill. $ - mill. $ -0.179 mill. 949 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.423 mill.
$ - mill.


$ -0.179 mill.
Employees Shares Outstanding P/E

-
949 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


NWBO

$0.352

$0.1397 65.80%
This Month of April


NWBO

$0.352

$0.1397 65.80%



Northwest Biotherapeutics Inc

Northwest Biotherapeutics Inc stock increased 65.80% during this month of April.


Northwest Biotherapeutics Inc*s business model focuses on the development and commercialization of personalized immunotherapy products for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 428.394 mill. $ 1.382 mill. $ -85.192 mill. 1,217 mill. - Y/Y -43.10 %
Market Cap. Revenues TTM Net Income TTM

$ 428.394 mill.
$ 1.382 mill.


$ -85.192 mill.
Employees Shares Outstanding P/E

25
1,217 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -43.10 %
MRQ Y/Y - %


QTTB

$2.07

$0.5700 38.00%
This Month of April


QTTB

$2.07

$0.5700 38.00%



Q32 Bio Inc

Q32 Bio Inc shares improved 38.00% during this month of April.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 15.016 mill. $ - mill. $ -47.733 mill. 7 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 15.016 mill.
$ - mill.


$ -47.733 mill.
Employees Shares Outstanding P/E

42
7 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


QURE

$13.26

$3.3500 33.80%
This Month of April


QURE

$13.26

$3.3500 33.80%



Uniqure N v

Uniqure N V stock increased 33.80% during this month of April.


Uniqure N.V*s business model revolves around developing and commercializing gene therapies to address rare genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 645.633 mill. $ 27.119 mill. $ -239.556 mill. 49 mill. - Y/Y 271.07 %
Market Cap. Revenues TTM Net Income TTM

$ 645.633 mill.
$ 27.119 mill.


$ -239.556 mill.
Employees Shares Outstanding P/E

80
49 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 271.07 %
MRQ Y/Y - %


RGBP

$0.0599

$0.0099 19.80%
This Month of April


RGBP

$0.0599

$0.0099 19.80%



Regen Biopharma Inc

Regen Biopharma Inc shares went up 19.80% during this month of April.


Regen Biopharma Inc is a biotechnology company that focuses on developing innovative treatments for diseases like cancer and autoimmune disorders. Their business model revolves around conducting research and development activities to create novel therapeutics and licensing or partnering with larger pharmaceutical companies for further development and commercialization. By leveraging their scientific expertise and strategic collaborations, Regen Biopharma aims to bring cutting-edge medical solutions to the market and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.252 mill. $ 0.154 mill. $ -0.860 mill. 4 mill. 20.66 Y/Y 86.68 %
Market Cap. Revenues TTM Net Income TTM

$ 0.252 mill.
$ 0.154 mill.


$ -0.860 mill.
Employees Shares Outstanding P/E

3
4 mill.
20.66
Revenue Growth Income Growth

MRQ Y/Y 86.68 %
MRQ Y/Y - %


BIXT

$0.1794

$0.0294 19.60%
This Month of April


BIXT

$0.1794

$0.0294 19.60%



Bioxytran Inc

Bioxytran Inc stock went up 19.60% during this month of April.


Bioxytran Inc*s business model revolves around developing and commercializing innovative therapeutic solutions, specifically focusing on oxygen therapeutics for various medical applications.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 21.229 mill. $ - mill. $ -2.380 mill. 118 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 21.229 mill.
$ - mill.


$ -2.380 mill.
Employees Shares Outstanding P/E

-
118 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ZVSA

$0.7001

$0.1126 19.17%
This Month of April


ZVSA

$0.7001

$0.1126 19.17%



Zyversa Therapeutics Inc

Zyversa Therapeutics Inc shares went up 19.17% during this month of April.


Zyversa Therapeutics Inc*s business model revolves around developing innovative therapies and treatments for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.777 mill. $ - mill. $ -9.413 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.777 mill.
$ - mill.


$ -9.413 mill.
Employees Shares Outstanding P/E

-
1 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


EGRX

$1.8

$0.2500 16.13%
This Month of April


EGRX

$1.8

$0.2500 16.13%



Eagle Pharmaceuticals inc

Eagle Pharmaceuticals Inc shares improved 16.13% during this month of April.


Eagle Pharmaceuticals is a specialty pharmaceutical company that focuses on developing and commercializing injectable products. Their business model revolves around identifying existing drugs and developing innovative formulations or delivery systems that offer distinct advantages. They primarily target niche markets, partnering with contract manufacturers to efficiently produce and distribute their products to healthcare providers and patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23.678 mill. $ 257.551 mill. $ 11.948 mill. 13 mill. 2.01 Y/Y -12.80 %
Market Cap. Revenues TTM Net Income TTM

$ 23.678 mill.
$ 257.551 mill.


$ 11.948 mill.
Employees Shares Outstanding P/E

117
13 mill.
2.01
Revenue Growth Income Growth

MRQ Y/Y -12.80 %
MRQ Y/Y - %


AXIM

$0.0041

$0.0005 13.89%
This Month of April


AXIM

$0.0041

$0.0005 13.89%



Axim Biotechnologies Inc

Axim Biotechnologies Inc stock improved 13.89% during this month of April.


Axim Biotechnologies Inc*s business model revolves around developing and commercializing innovative pharmaceutical and nutraceutical products, primarily focusing on cannabinoid-based therapies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.931 mill. $ 0.093 mill. $ -4.136 mill. 227 mill. - Y/Y 76.04 %
Market Cap. Revenues TTM Net Income TTM

$ 0.931 mill.
$ 0.093 mill.


$ -4.136 mill.
Employees Shares Outstanding P/E

45
227 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 76.04 %
MRQ Y/Y - %


XENE

$34.07

$3.4300 11.19%
This Month of April


XENE

$34.07

$3.4300 11.19%



Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc shares went up 11.19% during this month of April.


Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,652.366 mill. $ - mill. $ -234.330 mill. 78 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,652.366 mill.
$ - mill.


$ -234.330 mill.
Employees Shares Outstanding P/E

142
78 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ZBIO

$8.335

$0.7350 9.67%
This Month of April


ZBIO

$8.335

$0.7350 9.67%



Zenas Biopharma Inc

Zenas Biopharma Inc stock increased 9.67% during this month of April.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 110.050 mill. $ - mill. $ -204.919 mill. 13 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 110.050 mill.
$ - mill.


$ -204.919 mill.
Employees Shares Outstanding P/E

130
13 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


RCKT

$6.315

$0.5050 8.69%
This Month of April


RCKT

$6.315

$0.5050 8.69%



Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc stock increased 8.69% during this month of April.


Rocket Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of gene therapies for rare and devastating diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 598.528 mill. $ - mill. $ -258.746 mill. 95 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 598.528 mill.
$ - mill.


$ -258.746 mill.
Employees Shares Outstanding P/E

143
95 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


XLO

$0.7351

$0.0541 7.94%
This Month of April


XLO

$0.7351

$0.0541 7.94%



Xilio Therapeutics Inc

Xilio Therapeutics Inc shares went up 7.94% during this month of April.


Xilio Therapeutics Inc is a biotechnology company focused on developing and commercializing novel immunotherapies to treat cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 39.278 mill. $ 6.344 mill. $ -58.241 mill. 53 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 39.278 mill.
$ 6.344 mill.


$ -58.241 mill.
Employees Shares Outstanding P/E

64
53 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ACUT

$0.56

$0.0400 7.69%
This Month of April


ACUT

$0.56

$0.0400 7.69%



Accustem Sciences Inc

Accustem Sciences Inc shares went up 7.69% during this month of April.


Accustem Sciences Inc is a company that operates on a subscription-based business model with a focus on providing personalized health solutions. They offer genetic testing services and use the results to create customized plans, including nutrition and exercise recommendations, to improve overall health and prevent diseases. The company aims to enhance the well-being of individuals by leveraging genetic insights and promoting proactive health management.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.484 mill. $ - mill. $ -1.505 mill. 12 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.484 mill.
$ - mill.


$ -1.505 mill.
Employees Shares Outstanding P/E

-
12 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


PRLD

$0.828

$0.0577 7.49%
This Month of April


PRLD

$0.828

$0.0577 7.49%



Prelude Therapeutics Inc

Prelude Therapeutics Inc stock increased 7.49% during this month of April.


Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 62.678 mill. $ 7.000 mill. $ -127.173 mill. 76 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 62.678 mill.
$ 7.000 mill.


$ -127.173 mill.
Employees Shares Outstanding P/E

17
76 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


XOMA

$20.585

$1.2850 6.66%
This Month of April


XOMA

$20.585

$1.2850 6.66%



Xoma Royalty Corporation

Xoma Royalty Corporation stock went up 6.66% during this month of April.


Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 240.695 mill. $ 28.487 mill. $ -19.293 mill. 12 mill. - Y/Y 375.40 %
Market Cap. Revenues TTM Net Income TTM

$ 240.695 mill.
$ 28.487 mill.


$ -19.293 mill.
Employees Shares Outstanding P/E

13
12 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 375.40 %
MRQ Y/Y - %


RARE

$35.56

$1.7200 5.08%
This Month of April


RARE

$35.56

$1.7200 5.08%



Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc shares went up 5.08% during this month of April.


Ultragenyx Pharmaceutical Inc*s business model focuses on developing and commercializing innovative therapies for rare genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,217.829 mill. $ 560.230 mill. $ -569.183 mill. 90 mill. - Y/Y 29.42 %
Market Cap. Revenues TTM Net Income TTM

$ 3,217.829 mill.
$ 560.230 mill.


$ -569.183 mill.
Employees Shares Outstanding P/E

1,276
90 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 29.42 %
MRQ Y/Y - %


RAPP

$10.01

$0.4500 4.71%
This Month of April


RAPP

$10.01

$0.4500 4.71%



Rapport Therapeutics Inc

Rapport Therapeutics Inc stock went up 4.71% during this month of April.





Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 207.369 mill. $ - mill. $ -78.307 mill. 21 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 207.369 mill.
$ - mill.


$ -78.307 mill.
Employees Shares Outstanding P/E

-
21 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


LLY

$839.96

$34.7300 4.31%
This Month of April


LLY

$839.96

$34.7300 4.31%



Eli Lilly And Company

Eli Lilly And Company stock improved 4.31% during this month of April.


Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 759,622.237 mill. $ 45,042.700 mill. $ 10,590.000 mill. 904 mill. 71.89 Y/Y 44.68 %
Market Cap. Revenues TTM Net Income TTM

$ 759,622.237 mill.
$ 45,042.700 mill.


$ 10,590.000 mill.
Employees Shares Outstanding P/E

43,000
904 mill.
71.89
Revenue Growth Income Growth

MRQ Y/Y 44.68 %
MRQ Y/Y 101.39 %


SYRS

$0.0269

$0.0011 4.26%
This Month of April


SYRS

$0.0269

$0.0011 4.26%



Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc stock improved 4.26% during this month of April.


Syros Pharmaceuticals Inc operates based on a business model focused on developing targeted gene control therapies to treat various diseases. The company aims to leverage its gene control platform to identify and exploit unique gene regulatory networks to discover and develop novel therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.058 mill. $ - mill. $ -97.815 mill. 39 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.058 mill.
$ - mill.


$ -97.815 mill.
Employees Shares Outstanding P/E

47
39 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


PLRX

$1.425

$0.0550 4.01%
This Month of April


PLRX

$1.425

$0.0550 4.01%



Pliant Therapeutics Inc

Pliant Therapeutics Inc stock improved 4.01% during this month of April.


Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 86.364 mill. $ - mill. $ -210.304 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 86.364 mill.
$ - mill.


$ -210.304 mill.
Employees Shares Outstanding P/E

26
61 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


ETST

$0.135

$0.0050 3.85%
This Month of April


ETST

$0.135

$0.0050 3.85%



Earth Science Tech Inc

Earth Science Tech Inc stock increased 3.85% during this month of April.


Earth Science Tech Inc is a biotechnology company focused on developing and marketing innovative hemp cannabinoid-based products. Their business model revolves around research, development, manufacturing, and distribution of high-quality CBD and nutraceuticals for various industries, including the pharmaceutical and nutrition sectors.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 40.890 mill. $ 30.870 mill. $ 2.313 mill. 303 mill. 19.29 Y/Y 117.75 %
Market Cap. Revenues TTM Net Income TTM

$ 40.890 mill.
$ 30.870 mill.


$ 2.313 mill.
Employees Shares Outstanding P/E

-
303 mill.
19.29
Revenue Growth Income Growth

MRQ Y/Y 117.75 %
MRQ Y/Y -8.44 %


RDY

$13.645

$0.4850 3.69%
This Month of April


RDY

$13.645

$0.4850 3.69%



Dr Reddy s Laboratories Limited

Dr Reddy S Laboratories Limited stock increased 3.69% during this month of April.


Dr. Reddy*s Laboratories Ltd is a multinational pharmaceutical company that operates on a vertically integrated business model. They focus on the development, manufacturing, and marketing of a wide range of generic and branded pharmaceutical products. By leveraging their strong research and development capabilities and global presence, they aim to provide affordable and high-quality healthcare solutions to patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11,352.210 mill. $ 3,350.000 mill. $ 668.000 mill. 832 mill. 17.01 Y/Y 11.97 %
Market Cap. Revenues TTM Net Income TTM

$ 11,352.210 mill.
$ 3,350.000 mill.


$ 668.000 mill.
Employees Shares Outstanding P/E

22,000
832 mill.
17.01
Revenue Growth Income Growth

MRQ Y/Y 11.97 %
MRQ Y/Y 21.90 %


PYXS

$0.945

$0.0300 3.28%
This Month of April


PYXS

$0.945

$0.0300 3.28%



Pyxis Oncology Inc

Pyxis Oncology Inc shares increased 3.28% during this month of April.


Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 55.362 mill. $ - mill. $ -77.331 mill. 59 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 55.362 mill.
$ - mill.


$ -77.331 mill.
Employees Shares Outstanding P/E

10
59 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


OTLC

$0.0584

$0.0018 3.18%
This Month of April


OTLC

$0.0584

$0.0018 3.18%



Oncotelic Therapeutics Inc

Oncotelic Therapeutics Inc stock increased 3.18% during this month of April.


Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23.786 mill. $ - mill. $ -4.916 mill. 407 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 23.786 mill.
$ - mill.


$ -4.916 mill.
Employees Shares Outstanding P/E

5
407 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


PULM

$6.317

$0.1820 2.97%
This Month of April


PULM

$6.317

$0.1820 2.97%



Pulmatrix Inc

Pulmatrix Inc stock increased 2.97% during this month of April.


Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 23.047 mill. $ 7.806 mill. $ -9.559 mill. 4 mill. - Y/Y -99.86 %
Market Cap. Revenues TTM Net Income TTM

$ 23.047 mill.
$ 7.806 mill.


$ -9.559 mill.
Employees Shares Outstanding P/E

13
4 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -99.86 %
MRQ Y/Y - %


JNJ

$157.47

$4.2200 2.75%
This Month of April


JNJ

$157.47

$4.2200 2.75%



Johnson and Johnson

Johnson And Johnson stock went up 2.75% during this month of April.


Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 382,551.472 mill. $ 88,821.000 mill. $ 14,066.000 mill. 2,429 mill. 27.12 Y/Y 5.26 %
Market Cap. Revenues TTM Net Income TTM

$ 382,551.472 mill.
$ 88,821.000 mill.


$ 14,066.000 mill.
Employees Shares Outstanding P/E

134,400
2,429 mill.
27.12
Revenue Growth Income Growth

MRQ Y/Y 5.26 %
MRQ Y/Y -15.26 %


PRTG

$8.39

$0.1300 1.57%
This Month of April


PRTG

$8.39

$0.1300 1.57%



Portage Biotech Inc

Portage Biotech Inc stock increased 1.57% during this month of April.


Portage Biotech Inc.*s business model involves the identification and development of innovative therapeutics and healthcare solutions, leveraging a unique portfolio of biotechnology companies and their technologies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.406 mill. $ - mill. $ -75.382 mill. 0 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.406 mill.
$ - mill.


$ -75.382 mill.
Employees Shares Outstanding P/E

11
0 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


RCUS

$7.83

$0.1200 1.56%
This Month of April


RCUS

$7.83

$0.1200 1.56%



Arcus Biosciences Inc

Arcus Biosciences Inc stock improved 1.56% during this month of April.


Arcus Biosciences Inc is a biotechnology company that focuses on developing immuno-oncology therapies. Their business model revolves around discovering and developing novel small molecule and antibody therapeutics to target various cancer indications. They aim to combine their extensive understanding of the immune system with innovative technology platforms to create effective treatments for patients with cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 705.697 mill. $ 258.000 mill. $ -283.000 mill. 90 mill. - Y/Y -16.13 %
Market Cap. Revenues TTM Net Income TTM

$ 705.697 mill.
$ 258.000 mill.


$ -283.000 mill.
Employees Shares Outstanding P/E

21,164
90 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -16.13 %
MRQ Y/Y - %


PPBT

$2.6768

$0.0368 1.39%
This Month of April


PPBT

$2.6768

$0.0368 1.39%



Purple Biotech Ltd

Purple Biotech Ltd stock improved 1.39% during this month of April.


Purple Biotech Ltd is a biopharmaceutical company that focuses on developing innovative therapeutic solutions for various diseases. They generate revenue by licensing out their technology and products, as well as through collaborations and partnerships with other industry players.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ - mill. $ 21.760 mill. - mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ - mill.
$ - mill.


$ 21.760 mill.
Employees Shares Outstanding P/E

-
- mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y 17.83 %


PTCT

$47.14

$0.5400 1.16%
This Month of April


PTCT

$47.14

$0.5400 1.16%



Ptc Therapeutics inc

Ptc Therapeutics Inc shares increased 1.16% during this month of April.


PTC Therapeutics Inc*s business model revolves around the research, development, and commercialization of innovative treatments for rare and genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,620.661 mill. $ 900.028 mill. $ -320.204 mill. 77 mill. - Y/Y -12.88 %
Market Cap. Revenues TTM Net Income TTM

$ 3,620.661 mill.
$ 900.028 mill.


$ -320.204 mill.
Employees Shares Outstanding P/E

995
77 mill.
-
Revenue Growth Income Growth

MRQ Y/Y -12.88 %
MRQ Y/Y - %


XBIT

$3.04

$0.0200 0.66%
This Month of April


XBIT

$3.04

$0.0200 0.66%



Xbiotech Inc

Xbiotech Inc stock went up 0.66% during this month of April.


Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 92.964 mill. $ - mill. $ -38.531 mill. 31 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 92.964 mill.
$ - mill.


$ -38.531 mill.
Employees Shares Outstanding P/E

32
31 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


YMAB

$4.505

$0.0050 0.11%
This Month of April


YMAB

$4.505

$0.0050 0.11%



Y mabs Therapeutics inc

Y Mabs Therapeutics Inc stock increased 0.11% during this month of April.


Ymabs Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 199.471 mill. $ 87.684 mill. $ -29.666 mill. 44 mill. - Y/Y 29.53 %
Market Cap. Revenues TTM Net Income TTM

$ 199.471 mill.
$ 87.684 mill.


$ -29.666 mill.
Employees Shares Outstanding P/E

100
44 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 29.53 %
MRQ Y/Y - %


BPTH

$0.165

$0.0000 0.00%
This Month of April


BPTH

$0.165

$0.0000 0.00%



Bio path Holdings inc

Bio Path Holdings Inc shares went down 0.00% during this month of April.


Bio path Holdings Inc is a biotechnology company focused on developing RNA-based therapeutics for the treatment of diseases such as cancer. Their business model involves researching, developing, and commercializing these therapies to provide improved treatment options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.396 mill. $ - mill. $ -9.894 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.396 mill.
$ - mill.


$ -9.894 mill.
Employees Shares Outstanding P/E

9
2 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


INBP

$0.29

$0.0000 0.00%
This Month of April


INBP

$0.29

$0.0000 0.00%



Integrated Biopharma Inc

Integrated Biopharma Inc shares went down 0.00% during this month of April.


Integrated Biopharma Inc*s business model can be described as a vertically integrated health and wellness company focused on producing and distributing nutritional and dietary supplements.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.078 mill. $ 52.074 mill. $ 0.928 mill. 31 mill. 10.36 Y/Y 15.69 %
Market Cap. Revenues TTM Net Income TTM

$ 9.078 mill.
$ 52.074 mill.


$ 0.928 mill.
Employees Shares Outstanding P/E

50
31 mill.
10.36
Revenue Growth Income Growth

MRQ Y/Y 15.69 %
MRQ Y/Y - %


PTIX

$0.25

$0.0000 0.00%
This Month of April


PTIX

$0.25

$0.0000 0.00%



Protagenic Therapeutics Inc new

Protagenic Therapeutics Inc New stock declined 0.00% during this month of April.


Protagenic Therapeutics Inc has developed a novel business model focused on the discovery and development of novel therapeutics targeting the PGRMC1 receptor, which plays a crucial role in various diseases. By leveraging their proprietary technology and partnerships, the company aims to advance the development of innovative drugs that can effectively treat a range of conditions influenced by the PGRMC1 receptor.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.222 mill. $ - mill. $ -5.525 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.222 mill.
$ - mill.


$ -5.525 mill.
Employees Shares Outstanding P/E

10
5 mill.
-
Revenue Growth Income Growth

MRQ Y/Y - %
MRQ Y/Y - %


STAB

$0.0001

$0.0000 0.00%
This Month of April


STAB

$0.0001

$0.0000 0.00%



Statera Biopharma Inc fka Cytocom Inc

Statera Biopharma Inc Fka Cytocom Inc stock dropped 0.00% during this month of April.


Statera Biopharma Inc, formerly known as Cytocom Inc, operates as a biotechnology company focused on the development and commercialization of novel immunotherapies for the treatment of cancer and autoimmune diseases. Their business model revolves around advancing their pipeline of therapeutic candidates through preclinical and clinical trials, with the aim to bring innovative treatments to market that can improve patient outcomes and address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.005 mill. $ 3.688 mill. $ -102.535 mill. 50 mill. - Y/Y 183.48 %
Market Cap. Revenues TTM Net Income TTM

$ 0.005 mill.
$ 3.688 mill.


$ -102.535 mill.
Employees Shares Outstanding P/E

-
50 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 183.48 %
MRQ Y/Y - %


XBIO

$2.46

$0.0000 0.00%
This Month of April


XBIO

$2.46

$0.0000 0.00%



Xenetic Biosciences Inc

Xenetic Biosciences Inc stock dropped 0.00% during this month of April.


Xenetic Biosciences Inc is a biopharmaceutical company that focuses on developing personalized therapeutics with the potential to improve patient outcomes. The company employs a business model centered around leveraging its proprietary drug development platform to partner with pharmaceutical companies and advance novel drug candidates through preclinical and clinical stages.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3.791 mill. $ 2.500 mill. $ -3.960 mill. 2 mill. - Y/Y 6.16 %
Market Cap. Revenues TTM Net Income TTM

$ 3.791 mill.
$ 2.500 mill.


$ -3.960 mill.
Employees Shares Outstanding P/E

11
2 mill.
-
Revenue Growth Income Growth

MRQ Y/Y 6.16 %
MRQ Y/Y - %


ABT

$130.98

$-0.7100 -0.54%
This Month of April


ABT

$130.98

$-0.7100 -0.54%



Abbott Laboratories

Abbott Laboratories stock went down -0.54% during this month of April.


Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 229,763.607 mill. $ 41,950.000 mill. $ 13,402.000 mill. 1,754 mill. 17.07 Y/Y 7.16 %
Market Cap. Revenues TTM Net Income TTM

$ 229,763.607 mill.
$ 41,950.000 mill.


$ 13,402.000 mill.
Employees Shares Outstanding P/E

114,000
1,754 mill.
17.07
Revenue Growth Income Growth

MRQ Y/Y 7.16 %
MRQ Y/Y 478.98 %


PTGX

$46.08

$-0.8000 -1.71%
This Month of April


PTGX

$46.08

$-0.8000 -1.71%



Protagonist Therapeutics inc

Protagonist Therapeutics Inc shares dropped -1.71% during this month of April.


Protagonist Therapeutics Inc*s business model focuses on the development and commercialization of novel peptide-based therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,997.793 mill. $ 434.433 mill. $ 275.188 mill. 65 mill. 11.67 Y/Y 184.40 %
Market Cap. Revenues TTM Net Income TTM

$ 2,997.793 mill.
$ 434.433 mill.


$ 275.188 mill.
Employees Shares Outstanding P/E

112
65 mill.
11.67
Revenue Growth Income Growth

MRQ Y/Y 184.40 %
MRQ Y/Y 381.70 %



 1 Day   Week  Current Month of April  30 Days 
Current Quarter Q2 of 2025  90 Days    Ytd    12 Months 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com